CCEB Seminar-Anna Broder, MD, MSc

"Utilization of hydroxychloroquine and corticosteroids among lupus patients after new-onset end-stage renal disease onset: A longitudinal study using USRDS registry"Anna Broder, MD, MSc Department of Medicine, Division of Rheumatology Albert Einstein College of Medicine Bronx, NY Dr. Anna Broder's research focuses on improving outcomes in systemic lupus erythematosus and inflammatory arthropathies. She also studies how cardiovascular disease, kidney disease, and the presence of antiphospholipid antibodies affect outcomes in autoimmune diseases. She has experience working with large cohorts and databases, as well as with recruiting lupus and rheumatoid arthritis patients for ongoing clinical trials.Dr. Broder is the Primary Investigator for the Einstein Rheumatic Diseases registry that includes clinical data and samples for over 1000 patients with rheumatologic diseases. The primary focus of her research is lupus-related kidney disease. She is studying lupus activity and medications in patients with lupus-related end stage kidney disease. Dr. Broder is investigating the biomarkers of tubulointerstitial damage in early lupus nephritis in the hopes to prevent progression to end stage kidney disease. Her work is supported by funding from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).